title: Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) levels in patients with overt and subclinical hyperthyroidism: effects of treatment.
abstract: Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) has been shown to increase in parallel with platelet activation in acute ischaemic and thrombotic diseases. There has been no study evaluating SCUBE1 levels in patients with overt hyperthyroidism (OHyper) and subclinical hyperthyroidism (SHyper), conditions which are known to show impairment of both endothelial and platelet function. This study sought to evaluate SCUBE1 concentrations in patients with SHyper and OHyper, and assessed the effects of antithyroid drug (ATD) therapy on circulating SCUBE1 levels.
  
  
  
  Forty-five untreated patients with OHyper, 20 untreated patients with SHyper and 30 age- and sex-matched healthy controls were prospectively included in the study. Biochemical and hormonal parameters were evaluated in all patients before and after treatment.
  
  
  
  Compared with the control subjects, SCUBE1 levels were significantly increased in patients with SHyper and OHyper (P < 0·0001 and P = 0·002, respectively). SCUBE1 levels were not significantly different in patients with OHyper compared with patients with SHyper. There was no significant correlation between serum thyroid hormones and SCUBE1 levels. Plasma SCUBE1 levels decreased significantly in both OHyper and SHyper after ATD treatment (P < 0·05).
  
  
  
  Increased SCUBE1 levels in both SHyper and OHyper patients may reflect increased platelet activation and possible endothelial dysfunction, which might augment the risk for atherosclerotic and atherothrombotic complications. SCUBE1 may be used as a reliable marker of endothelial damage in hyperthyroidism, especially in the subclinical period.
authors.affiliation: Department of Internal Medicine, Division of Endocrinology and Metabolism, Trabzon, Turkey.
authors.forename: Cihangir
authors.initials: C
authors.lastname: Erem
authors.affiliation: Department of Internal Medicine, Division of Endocrinology and Metabolism, Trabzon, Turkey.
authors.forename: Nadim
authors.initials: N
authors.lastname: Civan
authors.affiliation: Department of Internal Medicine, Division of Endocrinology and Metabolism, Trabzon, Turkey.
authors.forename: Hulya
authors.initials: H
authors.lastname: Coskun
authors.affiliation: Department of Medical Biochemistry, Trabzon, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Mentese
authors.affiliation: Department of Internal Medicine, Division of Endocrinology and Metabolism, Trabzon, Turkey.
authors.forename: Akile Karacin
authors.initials: AK
authors.lastname: Suleyman
authors.affiliation: Department of Medical Biochemistry, Trabzon, Turkey.
authors.forename: Diler Us
authors.initials: DU
authors.lastname: Altay
authors.affiliation: Department of Public Health, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Akgul
authors.affiliation: Department of Medical Biochemistry, Trabzon, Turkey.
authors.forename: Orhan
authors.initials: O
authors.lastname: Deger
mesh_terms: D000328:Adult; D000368:Aged; D013956:Antithyroid Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002135:Calcium-Binding Proteins; D016022:Case-Control Studies; D004730:Endothelium, Vascular / Q000293:injuries / Q000503:physiopathology; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008565:Membrane Proteins / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D015539:Platelet Activation; D013963:Thyroid Hormones / Q000097:blood
chemical_list: D013956:Antithyroid Agents; D015415:Biomarkers; D002135:Calcium-Binding Proteins; D008565:Membrane Proteins; C469998:SCUBE1 protein, human; D013963:Thyroid Hormones